Vericel Reports Record Q2 Revenue and Raises Full-Year Guidance
Vericel Corporation (NASDAQ:VCEL) reported record second-quarter revenue of $77.5 million in July 2026, a 22% increase year over year. The company also raised its full-year revenue guidance to between $330 million and $340 million due to strong performance across both the MACI cartilage repair franchise and Burn Care business. MACI revenue reached a record $65.5 million, up 23% from last year, driven by an expanded sales force and increased adoption of its procedures among surgeons. The company also reported significant growth in biopsies and implants for this product line. In the Burn Care segment, revenue climbed to approximately $12 million, led by strong performance from Epicel and record NexoBrid sales. Vericel announced a new share repurchase program of up to $200 million as part of its commitment to returning value to shareholders while maintaining gross-margin and adjusted-EBITDA margin targets. The company ended the quarter with approximately $227 million in cash, supporting continued investment in growth initiatives.
Tickers: $VCEL
Topics: financial performance guidance update revenue growth share buybacks